85-90% of non-Hodgkin lymphoma cases are B-cell non-Hodgkin lymphoma (NHL). It is a cancer that develops from abnormal B lymphocytes and is caused by DNA mutations that disrupt cellular regulation, leading to uncontrolled growth. Common subtypes include diffuse large B-cell lymphoma (DLBCL, 33% of cases), follicular lymphoma, and mantle cell lymphoma. Treatment varies depending on the aggressiveness of the disease; aggressive types like DLBCL use chemotherapy (e.g., R-CHOP regimen) or radiation treatment. Risk factors include immune disorders and viral infections. The B cell non-Hodgkin lymphoma pipeline analysis by the publisher focuses on various treatment options for this disease.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to B cell non-Hodgkin lymphoma.
The course of treatment for B-cell non-Hodgkin lymphoma (B-NHL) depends on the patient's health, stage, and disease subtype. For aggressive types like diffuse large B-cell lymphoma (DLBCL), standard treatments include chemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Targeted medications like ibrutinib are used to block pathways that promote cell proliferation, whereas immunotherapy using monoclonal antibodies (such as rituximab) improves the targeting of cancerous cells. Stem cell transplants are saved for instances that have relapsed or are resistant, while radiation treats circumscribed cancers. Refractory illness may benefit from new CAR T-cell therapy. While late cases of indolent lymphomas require systemic treatment, early-stage cases may merely need to be monitored. Although the prognosis varies, frontline therapy for DLBCL has a 60-70% cure rate.
In the B cell non-Hodgkin lymphoma pipeline, nearly equal number of candidates are in Phase II and Phase I with 46% and 44% of the projects respectively followed by just 10% of projects in Phase III. Thus, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
This product will be delivered within 3-5 business days.
Report Coverage
The B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report by the publisher gives comprehensive insights into B cell non-Hodgkin lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for B cell non-Hodgkin lymphoma. The B cell non-Hodgkin lymphoma report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The B cell non-Hodgkin lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with B cell non-Hodgkin lymphoma treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to B cell non-Hodgkin lymphoma.
B Cell Non-Hodgkin Lymphoma Pipeline Outlook
B-cell non-Hodgkin lymphoma (B-NHL) develops in mature B-cells with genetic and epigenetic abnormalities. It is often involving dysregulated signaling pathways. Mutations in BCL6, BCL2, and MYC are important oncogenic drivers for the condition as they inhibit apoptosis and encourage unchecked proliferation. NF-?B is a vital survival pathway that is activated by persistent B-cell receptor (BCR) activation.The course of treatment for B-cell non-Hodgkin lymphoma (B-NHL) depends on the patient's health, stage, and disease subtype. For aggressive types like diffuse large B-cell lymphoma (DLBCL), standard treatments include chemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Targeted medications like ibrutinib are used to block pathways that promote cell proliferation, whereas immunotherapy using monoclonal antibodies (such as rituximab) improves the targeting of cancerous cells. Stem cell transplants are saved for instances that have relapsed or are resistant, while radiation treats circumscribed cancers. Refractory illness may benefit from new CAR T-cell therapy. While late cases of indolent lymphomas require systemic treatment, early-stage cases may merely need to be monitored. Although the prognosis varies, frontline therapy for DLBCL has a 60-70% cure rate.
B Cell Non-Hodgkin Lymphoma Epidemiology
With 85% of cases, B-cell non-Hodgkin lymphoma (B-NHL) is the most prevalent form of NHL. B-NHL is more common in men and older people, and NHL accounts for around 3% of cancer diagnoses and deaths worldwide. NHL accounts for 4% of all malignancies in the United States, and an estimated 80,350 additional cases are anticipated in 2025. Since 2015, incidence rates have decreased by 1% yearly, while therapeutic improvements have greatly increased survival.B Cell Non-Hodgkin Lymphoma - Pipeline Therapeutic Assessment
This section of the report covers the analysis of B cell non-Hodgkin lymphoma drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
By Route of Administration
- Oral
- Parenteral
- Others
B Cell Non-Hodgkin Lymphoma - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total B cell non-Hodgkin lymphoma clinical trials.In the B cell non-Hodgkin lymphoma pipeline, nearly equal number of candidates are in Phase II and Phase I with 46% and 44% of the projects respectively followed by just 10% of projects in Phase III. Thus, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
B Cell Non-Hodgkin Lymphoma - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the B cell non-Hodgkin lymphoma pipeline analysis include monoclonal antibody, peptides, small molecule and gene therapy. The B cell non-Hodgkin lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for B cell non-Hodgkin lymphoma.B Cell Non-Hodgkin Lymphoma Clinical Trials - Key Players
The report for the B cell non-Hodgkin lymphoma pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in B cell non-Hodgkin lymphoma clinical trials:- Merck Sharp & Dohme LLC
- Hoffmann-La Roche
- Novartis Pharmaceuticals
- Shanghai Cell Therapy Group Co.,Ltd
- Austin Health
- Genmab
- Kyowa Kirin Co., Ltd.
- Acerta Pharma BV
- Genentech, Inc.
- Shanghai Ming Ju Biotechnology Co., Ltd.
B Cell Non-Hodgkin Lymphoma Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for B cell non-Hodgkin lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of B cell non-Hodgkin lymphoma drug candidates.Drug: Glofitamab
Glofitamab, developed by Hoffmann-La Roche, is a bispecific monoclonal antibody designed to treat B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL). Currently in late Phase 1 clinical trials, it targets CD20 on B-cells and CD3 on T-cells, activating T-cells to destroy malignant B-cells. In studies, it achieved a 56% overall response rate, with cytokine release syndrome as the most common adverse event.Drug: Tisagenlecleucel
Tisagenlecleucel, marketed as Kymriah by Novartis Pharmaceuticals, is a chimeric antigen receptor (CAR) T-cell therapy designed to treat relapsed or refractory B-cell malignancies, including non-Hodgkin lymphoma. Currently in Phase 3 clinical trials, it modifies a patient’s T-cells to target CD19-expressing cancer cells. In the JULIET trial, it achieved a 52% overall response rate. Common side effects include cytokine release syndrome and neurological events.Key Questions Answered in the B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report
- Which companies/institutions are leading the B cell non-Hodgkin lymphoma drug development?
- What is the efficacy and safety profile of B cell non-Hodgkin lymphoma pipeline drugs?
- Which company is leading the B cell non-Hodgkin lymphoma pipeline development activities?
- What is the current B cell non-Hodgkin lymphoma commercial assessment?
- What are the opportunities and challenges present in the B cell non-Hodgkin lymphoma pipeline landscape?
- What is the efficacy and safety profile of B cell non-Hodgkin lymphoma pipeline drugs?
- Which company is conducting major trials for B cell non-Hodgkin lymphoma drugs?
- Which companies/institutions are involved in B cell non-Hodgkin lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in B cell non-Hodgkin lymphoma?
Reasons To Buy This Report
The B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for B cell non-Hodgkin lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into B cell non-Hodgkin lymphoma collaborations, regulatory environments, and potential growth opportunities.This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of B Cell Non-Hodgkin Lymphoma
4 Patient Profile: B Cell Non-Hodgkin Lymphoma
5 B Cell Non-Hodgkin Lymphoma: Epidemiology Snapshot
6 B Cell Non-Hodgkin Lymphoma: Market Dynamics
7 B Cell Non-Hodgkin Lymphoma: Key Facts Covered
8 B Cell Non-Hodgkin Lymphoma, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 B Cell Non-Hodgkin Lymphoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 B Cell Non-Hodgkin Lymphoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 B Cell Non-Hodgkin Lymphoma Drug Pipeline - Mid-Stage Products (Phase I) (Top Drugs)
13 B Cell Non-Hodgkin Lymphoma, Key Drug Pipeline Companies
